Bayer's $7.25 Billion Legal Reckoning Looms as Japan Approval Bolsters Oncology Turnaround

Bayer secures Japan approval for Hyrnuo in lung cancer, boosting oncology pipeline as Roundup settlement hearing looms; stock up 32% YTD.

The German conglomerate has spent years trying to rewrite its narrative — one defined as much by courtroom battles as by laboratory breakthroughs. This week, the pharma and chemicals group added another chapter to the turnaround story, securing Japanese regulatory approval for Hyrnuo, the brand name for its drug Sevabertinib, in patients with HER2-mutant, unresectable non-small cell lung cancer.

The green light from Japanese authorities marks the second regulatory win for Bayer's oncology division in a matter of weeks and lands at a critical juncture. The company is simultaneously preparing for a September 14 court hearing that will determine whether its $7.25 billion Roundup settlement receives final judicial approval — a decision that could reshape the investment case for the stock.

A Pipeline Counterweight to Legal Headwinds

The Japan approval underscores how aggressively Bayer is pivoting its pharma segment toward oncology as a growth engine, even as the glyphosate litigation continues to cast a long shadow. For a company wrestling with both legal liabilities and a substantial debt load, the regulatory milestone signals that operational execution remains on track despite the financial strain emanating from the US courtroom battles.

That operational narrative was already taking shape in the second quarter. Bayer reported currency-adjusted revenue growth of 2.2 percent, reaching EUR 10.9 billion, with EBITDA before special items coming in at EUR 2.1 billion. Chief Executive Bill Anderson struck a confident tone, stating the company is "operationally on a good path to achieve its annual targets." The results, which management emphasized exceeded expectations, were framed around operational delivery and continued deleveraging — priorities that resonate with investors given the balance sheet pressures.

The agricultural division has also contributed to the momentum. Partner MustGrow Biologics confirmed on Friday that it had received an initial milestone payment from Bayer under their existing collaboration agreement.

Stock Holds Near Highs Despite Legal Overhang

The market has taken notice of the operational progress, even with the unresolved glyphosate question hanging over the shares. Bayer stock closed Wednesday at EUR 48.92, down a marginal 0.6 percent on the day, but the medium-term picture tells a more constructive story. The shares have gained 4.0 percent over the past 30 days and are up 32 percent since the start of the year. Trading roughly 19 percent above the 200-day moving average of EUR 41.11, the technical setup points to an intact upward trend, though the stock still sits about 9 percent below its 52-week high of EUR 53.86 reached in early July.

Analyst enthusiasm has been building as well. In early August, several major banks lifted their price targets — Goldman Sachs set its at EUR 63.50, UBS at EUR 62, and JPMorgan at EUR 61, each with a positive rating. Those calls, however, are now more than three weeks old and reflect the sentiment of that moment rather than current positioning.

The September 14 Reckoning

For all the encouraging news from the pipeline and the operating businesses, the glyphosate settlement remains the dominant force driving the share price. The hearing for final court approval of the $7.25 billion Roundup settlement was originally scheduled for August 19 but did not take place and was pushed to September 14. This marks the second postponement of the hearing, and each delay prolongs the uncertainty that has weighed on valuation.

Investors are now left weighing two competing forces: tangible advances in drug development and commercial execution against the unresolved legal liability whose next pivotal moment arrives in just over two weeks. The September 14 decision will likely determine whether the operational gains — including this week's Japan approval — can be sustainably reflected in the share price, or whether the legal overhang continues to act as a brake on the stock's re-rating.

In a related but peripheral regulatory development, Bayer submitted its final statement to Germany's Federal Cartel Office in early August regarding the so-called 50+1 rule. That statement is legally non-binding and carries limited significance for the company's core operations, but it adds another layer to the complex web of regulatory proceedings surrounding the group.

For now, the two-track story remains intact: a company making credible strides in its labs and its operating divisions, still awaiting the courtroom verdict that could define its financial trajectory for years to come.